Biogen Inc. ( NASDAQ: BIIB) Stifel 2025 Virtual CNS Forum Conference March 18, 2025 10:15 AM ET Great. Good morning, everybody. Happy to be moderating my annual panel where Priya has to listen to me ...

INmune Bio's high-upside potential with CORDStrom for RDEB and XPro for Alzheimer's, offering up to 144.8x returns. Click ...

Eisai has filed to extend the label for its Alzheimer’s disease therapy Leqembi to include a maintenance dosing regimen that would reduce the number of intravenous infusions needed to one per month.

Eisai and Biogen's Alzheimer's therapy Leqembi will be priced at $26,500 per year – a little less than misfired predecessor Aduhelm – after getting conditional authorisation for the drug from ...

Kisunla differs from its competitor therapy, Leqembi, manufactured by Biogen and Eisai, in that it needs to be administered every four weeks versus every two weeks. Lilly has also continued to ...

In 2024, drugmakers delivered breakthrough treatments in conditions that had seen little progress for decades—and helped make existing therapies more accessible. Approved in July, Eli Lilly’s ...

Enzyme mechanisms are the chemical transformations, and the steps within them, generated by enzymatic action on substrates. The mechanism of enzyme catalysis is similar in principle to other types ...

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), March 20, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of ...

Pre-clinical data suggest the primary mechanism of action of doxecitine and doxribtimine is the incorporation of nucleosides deoxycytidine (dC) and deoxythymidine (dT) into skeletal muscle ...

Soon-to-be medical school graduates received 877 more primary care position offers in the 2025 Main Residency Match compared with the previous year, according to the National Resident Matching ...

After hours: March 21 at 7:27:47 PM EDT Loading Chart for BIIB ...